Folha de evidência científica · Judici Cannabis
CBD é seguro e sem potencial de abuso
O canabidiol é bem tolerado e sem dependência? — Revisão crítica da OMS: bom perfil de segurança, sem abuso.
força líquida 0.36
consenso 87 · consenso forte
Emergente
24 estudos · 13 apoiam · 3 refutam
88% ≥2020
62% alto nível
📐 Números que convencem
reduz total bilirubin vs placebo (p=0.046)
Safety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial (2026) · medRxiv · DOI: 10.64898/2026.03.21.26348972
reduz total bilirubin vs placebo (p = 0.046)
Safety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial. (2026) · DOI: 10.1177/25785125261439014
79.3% alcançou uma redução ≥50% na frequência de crises
Adjunctive cannabidiol in intractable pediatric epilepsy: A retrospective study on tolerability, efficacy, and safety across genetic and nongenetic etiologies. (2026) · DOI: 10.1097/md.0000000000047425
69% alcançou redução de crises ≥50%
Real-world efficacy and safety of cannabidiol in developmental and epileptic encephalopathies. (2025) · DOI: 10.1002/epi4.70149
reduz NIH-CPSI em 7.0 pontos (P=0.003)
Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial. (2026) · DOI: 10.5507/bp.2026.002
50% dos pacientes atingiram redução de 3 pontos no escore de Mayo
Safety and Preliminary Clinical Outcomes of a Combined Cannabidiol and Sodium Propionate Enema in Refractory Ulcerative Proctitis: An Open-Label Pilot Study. (2026) · DOI: 10.1159/000552842
✅ Evidências que apoiam (13)
apoiaCannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke FM et al. (2012), Translational Psychiatry · ensaio clinico rct · força 0.94 · DOI
Melhora de sintomas psicóticos vs amisulprida, melhor tolerância
Melhora de sintomas psicóticos vs amisulprida, melhor tolerância
apoiaComparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru<sup>®</sup>, vs an Oil-Based Formulation, Epidyolex<sup>®</sup>, Under Fasted and Fed Conditions in Healthy Participants: A Randomized Open-Label Cross-Over Phase I Study.
Bendik I, Beck M, Manderna A, Roos FF, Wang J, McCarthy D et al. (2026) · ensaio clinico rct · força 0.93 · DOI
CBtru ® trended to higher CBD exposure vs Epidyolex ®
CBtru ® trended to higher CBD exposure vs Epidyolex ®
apoiaSafety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial
Couton C, Wanneveich M, De Dieuleveult B, Robin C, Ayena K, Harry A et al. (2026), medRxiv · ensaio clinico rct · força 0.93 · DOI
reduz total bilirubin vs placebo (p=0.046)
reduz total bilirubin vs placebo (p=0.046)
apoiaSafety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial.
Couton C, Wanneveich M, De Dieuleveult B, Robin C, Ayena K, Harry A et al. (2026) · ensaio clinico rct · força 0.93 · DOI
reduz total bilirubin vs placebo (p = 0.046)
reduz total bilirubin vs placebo (p = 0.046)
apoiaProspective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer (and elderly cohort)
Bar-Lev Schleider L et al. (2018), European Journal of Internal Medicine · coorte · força 0.80 · DOI
Melhora de dor/qualidade de vida; efeitos adversos leves
Melhora de dor/qualidade de vida; efeitos adversos leves
apoiaCARE - A Retrospective, Dual-Cohort, 24-Week Real-World Study from the German Pain e-Registry on the Effectiveness and Safety of CBD-Dominant Oral Cannabis Extracts versus THC/Dronabinol in Older Patients with Chronic Pain.
Überall MA, Müller-Schwefe PCG, Küster MA, Müller-Schwefe GHH (2026) · coorte · força 0.75 · DOI
CBD-dominant extracts associados a melhores resultados multidimensionais e melhor tolerabilidade que THC/DRO
CBD-dominant extracts associados a melhores resultados multidimensionais e melhor tolerabilidade que THC/DRO
apoiaAdjunctive cannabidiol in intractable pediatric epilepsy: A retrospective study on tolerability, efficacy, and safety across genetic and nongenetic etiologies.
Shim Y, Yang DH, Byeon JH, Eun BL (2026) · coorte · força 0.75 · DOI
79.3% alcançou uma redução ≥50% na frequência de crises
79.3% alcançou uma redução ≥50% na frequência de crises
apoiaReal-world efficacy and safety of cannabidiol in developmental and epileptic encephalopathies.
Perulli M, Bianchetti M, Pantalone G, Quintiliani M, Gambardella ML, Picilli M et al. (2025) · coorte · força 0.75 · DOI
69% alcançou redução de crises ≥50%
69% alcançou redução de crises ≥50%
apoiaCannabidiol (CBD) Critical Review Report
WHO Expert Committee on Drug Dependence (ECDD) (2018), Organização Mundial da Saúde · documento de politica · força 0.58
Sem potencial de abuso; bom perfil de segurança
Sem potencial de abuso; bom perfil de segurança
apoiaExploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study.
Costa GPA, Suh R, Sofuoglu M, De Aquino JP (2026) · ensaio clinico · força 0.33 · DOI
indica benefícios potenciais com 400 mg para indivíduos em buprenorfina
indica benefícios potenciais com 400 mg para indivíduos em buprenorfina
apoiaEarly-life exposure to Cannabidiol: Safety assessment of a chronic exposure in Caenorhabditis elegans.
Padilha HA, Reginatto JF, Saleh JD, Jardim NS, Crippa JA, Hallak JEC et al. (2026) · pre clinico · força 0.33 · DOI
CBD treatment early in life was safe at the lowest concentration
CBD treatment early in life was safe at the lowest concentration
apoiaCannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial.
Student V, Repa V, Vrbkova J, Vacek J (2026) · ensaio clinico · força 0.33 · DOI
reduz NIH-CPSI em 7.0 pontos (P=0.003)
reduz NIH-CPSI em 7.0 pontos (P=0.003)
⚠️ Evidências que refutam (3) — transparência
refutaCannabinoids in peripheral neuropathic pain: Resolving mechanistic mismatch through CB<sub>2</sub>-oriented phenotype stratification.
Bagher AM (2026) · força 1.00 · DOI
refutaCannabidiol as a treatment for cocaine use disorder: a scoping review.
Dos Santos LC, da Cunha VB, Ribeiro JM, Torres LHL, Garcia RCT (2026) · força 0.98 · DOI
refutaAdjunctive Cannabidiol in Inpatient Buprenorphine Treatment for Opioid Use Disorder: A Pilot Randomized Trial.
London ED, Dean AC, De La Garza R 2nd, Lachoff H, Mooney LJ, Torrington M et al. (2025) · força 0.94 · DOI
Folha gerada em 28/09/2026 pela plataforma Judici Cannabis. Evidência real e rastreável (DOI). 8 estudo(s) de contexto (revisões/mecanístico) não listados. Força líquida = apoio − refutação ponderado; maturidade por regras explícitas. Não substitui aconselhamento médico/jurídico.